JY231 injection for active lupus
Treatments studied
Part of Immune system & allergy, Skin clinical trials.
This trial tests an investigational drug called JY231 for people with active systemic lupus erythematosus (SLE) that is not well controlled with standard treatments. The goal is to see if JY231 can reduce lupus activity and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of lupus (SLE) based on standard medical criteria.
- Your lupus must still be active despite being on at least 2 months of combination treatment (like steroids plus an immunosuppressant or biologic).
- Blood tests must show certain lupus-related antibodies (like ANA or anti-dsDNA).
- Your disease activity score (SLEDAI-2K) must be higher than 6, with significant symptoms not just lab findings.
- You cannot have other serious autoimmune diseases or unstable lupus complications like severe kidney or brain involvement.
- You should not have had a recent infection requiring IV antibiotics or any history of certain serious infections like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
This trial tests a new treatment, JY231, for people with B-cell blood cancers that have come back or not responded to other treatments. It aims to see if this therapy can help when other options have stopped working.
This trial tests a new injection (JY231) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has not responded well to treatment or has come back. It aims to see if the treatment can help reduce cancer cells in the bone marrow.
This trial tests a new cell therapy called JY231 for people with certain autoimmune diseases like lupus or Sjögren's syndrome that haven't improved with standard treatments. The goal is to see if it can reduce disease activity.
This early-phase trial tests a new cell therapy called JY231 for people with severe autoimmune diseases like lupus, Sjogren's, scleroderma, dermatomyositis, or ANCA vasculitis that haven't improved with standard treatments. It aims to see if the therapy can help control the disease when other options have failed.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.